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Abstract
Background: Little is known about prognosis of metastatic patients after receiving a first-line treatment and failure. 
Our group already showed in pre-treated patients enrolled in phase I clinical trials that a performance status (PS) > 2 
and an LDH > 600 UI/L were independent prognostic factors. In this prospective study, which included 45 patients, we 
identified clinical and biological variables as outcome predictors in metastatic Non-Small Cell lung cancer after first line 
chemotherapy were identified.
Findings: Forty-five patients that were previously treated for metastatic disease from 12/2000 to 11/2005 in the 
comprehensive cancer centre (Centre Léon Bérard). Clinical assessment and blood parameters were recorded and 
considered. Patient prognostic factors for overall survival (OS) with a 0.05-significance level in univariate analysis were 
entered in a multivariate Cox model for further analysis.
Patients' median age was 58.5 years (range: 37 - 76). Sixty two percent of the patients were PS = 0 or 1. After inclusion, 
nine patients received second-line (22.5%), and two received third-line chemotherapy (5%). Univariate analysis showed 
that the factors associated with reduced OS were: PS > 2, weight loss >10%, more than one line of chemotherapy 
treatment and abnormal blood parameters (hemoglobin (Hb), platelet and neutrophils counts). Multiple regression 
analysis confirmed that PS > 2 and abnormal hemoglobin were independent predictors for low overall survival. 
According to the presence of none (33%), 1 (37%) and 2 (30%) prognostic factors, median OS were 12, 5 and 2 months 
respectively.
Conclusion: From this prospective study, both PS and anemia were found as independent determinants of survival, we 
found that both PS and anemia were independent determinants of survival. The combination of poor PS and anemia is 
an effective strategy to predict survival in the case of patients with metastatic NSCLC receiving further treatment after 
the first line.
Findings
Prediction of survival in the case of advanced non-small
cell lung cancer (NSCLC), when patients have already
received first line treatment, is critical to the decision of
subsequent treatments. Defining prognostic determi-
nants of NSCLC may help physicians to improve their
decisions making for both clinical trials and routine prac-
tice [1].
Many studies have reported predictive models for sur-
vival in metastatic cancers. These models integrated a
combination of clinical and biological factors. Biological
characteristics such as lactate dehydrogenase level (LDH)
[4], lymphocyte count [2,3], or Interleukin 6 level [5,6]
have been correlated with poor outcome in metastatic
cancer.
In this study, we aimed to identify clinical and biologi-
cal variables as outcome predictors for early death in
locally advanced or metastatic NSCLC in patients treated
beyond the first line chemotherapy failure.
Patients and methods
The investigation was a prospective, observational, sin-
gle-centre study.
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Inclusion criteria were: patients > 18 years old with
locally Advanced or metastatic NSCLC who were eligible
for further chemotherapy after first line chemotherapy
failure.
Exclusion criteria were: new patients who had not yet
received any chemotherapy.
Written consent was obtained from each patient. The
institutional ethics committee approved the study proto-
col before implementation, on March 17, 2000.
The primary objective of this study was to identify clin-
ical and biological variables as prognostic factors for met-
astatic NSCLC patients after failure of first line
chemotherapy.
These variables were collected at inclusion: age, gender,
Eastern Cooperative Oncology Group (ECOG) PS,
weight loss, number and sites of metastases, previous and
current chemotherapy regimens. In addition to labora-
tory tests which included complete blood accounts
(hemoglobin, neutrophils, lymphocytes), albumin, LDH
and C-reactive protein (CRP) levels. According to our
previous studies, the cutoff of each biological parameter
was defined as follows: the albumin level +/- 38 g/l, the
lymphocytes count +/- 700 μL [2,3], the LDH level +/-
600 U/L [4], and anemia was defined as hemoglobin level
(Hb) less than 11.5 g/dL for female and less than 13.0 g/
dL for male.
Statistical considerations
Survival analysis: the primary outcome was overall sur-
vival, defined as the time from inclusion to death or to
last follow-up. Survival distributions in prognostic
groups were estimated by the Kaplan-Meier method.
Univariate and multivariate analysis: to evaluate the
relationship between survival and baseline characteris-
tics, all clinical and biological variables were included in
univariate Cox proportional hazard regression models.
The log-rank test was used to compare survival curves.
Candidate prognostic factors for overall survival with a
0.05 level of significance in univariate analysis were
entered in a multivariate Cox model.
Results
Patients' characteristics (Table 1)
Between 2000 and 2005, 45 patients with metastatic
NSCLC were included in the study. Their characteristics
are summarized in table 1. Thirty patients were male
(75%) and fifteen female (25%). Median age was 58.5
years (range 37-76). Sixty two percent had PS 0 -1. Only 6
patients (14%) had a weight loss of 10% or more in the
previous six months.
All patients received platinum based first line chemo-
therapy. Prior to inclusion, 9 patients received second line
treatment and two patients received third line chemo-
Table 1: Patients' characteristics
Patients Characteristics Number (Percent)
Total 45 (100)
Age, years
Median 58.5
Range 34.7 - 76.9
Gender
Male 30 (66.7)
Female 15 (33.3)
ECOG Performance Status
Assessed by the physician
04  ( 9 . 3 )
1 23 (53.5)
>1 16 (37.2)
Self-assessed by the 
patient
00  ( 0 . 0 )
1 17 (37.8)
>1 28 (62.2)
Weight loss > 10% 6 (14.0)
Number of metastases
1 8 (18.2)
2 21 (47.7)
>2 15 (34.1)
Site of metastases
Bone 11 (24.4)
Liver 14 (31.1)
Lung 28 (62.2)
Brain 12 (26.7)
Previous treatment
Adjuvant chemotherapy 4 (8.9)
Treatment completed
First-line 29 (72.5)
Second-line 9 (22.5)
>Second-line 2 (5.0)
Treatment after inclusion
Palliative chemotherapy 45 (100.0)Belbaraka et al. BMC Research Notes 2010, 3:164
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therapy treatment (single agent Docetaxel or Gemcit-
abine).
Biological variables are summarized in Table 2. All lab-
oratory data were available for all patients. Majority of
the patients presented anemia (65%), low albumin level
(77.5%) and high CRP level (54%).
Survival
Because almost all patients died (42/45), the Kaplan-
Meier method have not been used to calculate the follow-
up. To estimate it, we provide the median of the delays of
survival for all patients, which was 3.1 months (range: 0.2
- 46.7 months).
Univariate analysis showed that six variables were cor-
related with poor outcome (p < 0.05).
As clinical parameters, we found PS > 1, weight loss
(<10%) and more than one line of chemotherapy treat-
ment. Anemia, platelet level < 130000 and IL6 > 8 pg/ml
were also associated with poor clinical outcome. Table 3
summarized results of prognostic parameters using uni-
variate and multivariate analysis.
Multivariate analysis showed that only two variables
were statistically correlated with significant poor progno-
sis (p < 0.05): PS > 1 and anemia. Figures 1 and 2 showed
the relationship between PS or Hb level and overall sur-
vival. The median survival was 2 months when PS > 1
versus 8 months when PS: 0-1. The median survival was 3
months when Hb level was abnormal versus 9 months
when Hb level was normal.
We can then define 4 groups of survival. Figure 3 show
the results of the analysis of 0, 1 or 2 prognostic factors
with Kaplan-Meier overall survival analysis. Group1 (13
patients) was a poor outcome group with only 1.9 months
median survival (CI95: 0.9-2.3) and had a PS > 1 and ane-
mia.
Group 2 (13 patients) was a good outcome group with
12.1 months median survival (CI95: 3.1-26.4) and had a
PS: 0-1 and normal Hb.
In addition, two intermediate groups were identified:
one with a PS > 1 and normal Hb (3 patients) and had a
median survival of 2.6 months (CI95: 2.3-NA), and a sec-
ond with a PS: 0-1 and anemia (14 patients) and had a
median survival of 5.3 months (CI95: 2.5-6.4).
Discussion
From this prospective study, we found that both PS and
anemia were independent prognostic factors of survival
for metastatic NSCLC patients who relapsed after the
first line chemotherapy. The combination of poor PS and
anemia is an effective strategy to predict survival and
then to select patients who may be will not benefit from
further chemotherapy.
Up till now, most widely accepted prognostic determi-
nants are disease stage and performance status [8]. Many
large trials considered other features such as male gender,
age older than 60 years, non-squamous histologics,
weight loss as stratification factors insofar as they have
been reported as negative prognostic factors [9].
As in other types of cancer, PS plays a clear prognostic
role in advanced NSCLC. In all the retrospective and pro-
spective trials regarding prognostic factors in this disease,
PS has been shown to be an independent prognostic
parameter [10].
Table 2: Biological tests
Parameters Number (Percent)
Hemoglobin
Abnormal (<11.5 g/dL 
for female; <13.0 g/dL 
for male)
29 (64.4)
Absolute Neutrophil Count
<2000/μL 1 (2.2)
2000-7500/μL 31 (68.9)
>7500/μL 13 (28.9)
Lymphocyte count
<700/μL 20 (46.5)
700-1000/μL 10 (23.3)
≥1000/μL 13 (30.2)
Missing data 2
Platelet count
<130 G/L 5 (11.1)
130-400 G/L 33 (73.3)
>400 G/L 7 (15.6)
Albumin
<38 g/L 31 (77.5)
Missing data 5
LDH
>600 U/L 10 (27.0)
Missing data 8
CRP
≤10 mg/L 15 (45.5)
10-50 mg/L 8 (24.2)
>50 mg/L 10 (30.3)
Missing data 12
LDH: lactate dehydrogenase; CRP: C-reactive protein;Belbaraka et al. BMC Research Notes 2010, 3:164
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Table 3: Prognostic parameters on univariate and multivariate analysis for lung cancer patients
Univariate analysis Multivariate analysis
HR 95% CI p HR 95% CI p
ECOG Performance Status assessed by the physician
0-1
>1
3.641 [1.743-7.607] 0.0006 3.279 [1.546-6.955] 0.0020
Hemoglobin
Normal
Abnormal†
2.941 [1.401-6.172] 0.0044 2.781 [1.290-5.997] 0.0091
Platelet count (G/L)
≥130
<130
4.023 [1.512-10.703] 0.0053 NS
Weight loss >10%
No
Yes
2.633 [1.079-6.423] 0.0334 NS
Number of metastases
≤2
>2
1.776 [0.913-3.453] 0.0904 NS
Number of chemotherapy lines
≤1
>1
0.0305 NS
Albumin (g/L)
≥38
<38
1.585 [0.722-3.481] 0.2510 -
CRP (mg/L)
≤10
>10
1.499 [0.718-3.132] 0.2812 -
Lymphocyte Count
≥700/μL
<700/μL
1.297 [0.684-2.462] 0.4258 -Belbaraka et al. BMC Research Notes 2010, 3:164
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For example, a series of 14 South Western Oncology
Group (SWOG) trials, where 2531 patients with inopera-
ble lung cancer were recruited during 1974 -1988 in order
to investigate the impact that 50 prognostic factors had
on survival, revealed that performance status, extent of
disease, and weight loss were among the most important
ones [11]. The median survival was found to be 6.7
months in PS 0,1 patients and 3. 8 months in PS 2
patients.
For patients with good PS, pretreatment Hb level >= 11
g/dl, normal LDH, calcium levels and a single metastatic
site were favorable factors [11]. A recursive partitioning
and amalgamation analysis showed that the best survival
occurred in patients with good PS who had Hb levels >=
11 g/dl and were older than 47 years.
Further more, the Eastern Cooperative Oncology
Group (ECOG) in a five phase II/III trials performed on
1960 patients with advanced NSCLC during 1981-1994
and treated with cisplatin-based chemotherapy showed a
median survival of 9.4 months for patients with PS0, 6.4
months for patients with PS1, and 3.3 months for patients
with PS2, confirming once again the prognostic value of
performance status [12,13].
In our study, performance status (PS) was also identi-
fied as independent prognostic factor. Median survival
was 8 months in PS: 0-1 patients, and 2 months in PS >1
patients.
Of all clinical and biological factors analyzed, PS and
anemia were the only variables statistically significant in
multivariate analysis. Neither presence of brain metasta-
ses nor a weight loss could predict patients' survival.
Anemia is commonly observed in lung cancer and is a
major contributing factor to fatigue and decreased qual-
ity of life (QOL) [14]. Hemoglobin levels at the time of
diagnosis can be considered as prognostic indicator in
patients with NSCLC. Low hemoglobin levels are associ-
ated with decreased survival. The evaluation of this
parameter can be used for a more accurate prognosis in
this disease and a better adequacy of therapeutic indica-
tions [15].
Anemia is the most frequently observed haematological
abnormality faced by cancer patients.
Liver metastases
No
Yes
0.809 [0.415-1.581] 0.5359 -
Quality of life using 0-10 VAS
≥5
<5
0.841 [0.445-1.592] 0.5953 -
Age (years)
≤60
>60
0.919 [0.495-1.710] 0.7907 -
Previous adjuvant chemotherapy
No
Yes
0.863 [0.265-2.816] 0.8074 -
LDH (U/L)
≤600
>600
1.079 [0.501-2.326] 0.8462 -
Absolute Neutrophil Count
≥2
<2
1.190 [0.161-8.801] 0.8648 -
LDH: lactate dehydrogenase; CRP: C-reactive protein; VAS: visual analog scale. †<11.5 g/dL for female; <13.0 g/dL for male
Table 3: Prognostic parameters on univariate and multivariate analysis for lung cancer patients (Continued)Belbaraka et al. BMC Research Notes 2010, 3:164
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Yet, its association to tumour biology is not well under-
Figure 1 Relationship between performance status and overall survival
Figure 2 Relationship between hemoglobin level and overall survivalBelbaraka et al. BMC Research Notes 2010, 3:164
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stood. Several recent retrospective clinical studies
showed that anemia is not only a negative prognostic fac-
tor but also, in some situations, a negative predictive
parameter in chemotherapy-treated patients with solid
tumours or haematological malignancies. These include
lymphomas, leukaemias, non-small-cell lung cancer,
ovarian cancer, cervical cancer, urothelial and renal can-
cers, and head and neck carcinoma [16,17].
The treatment of anemia in patients with cancer under-
going chemotherapy may improve outcome in terms of
both response rate to treatment and survival.
Several clinical signs have been shown to be prognosti-
cally important in terminally ill cancer patients [18].
Symptoms like anorexia-cachexia syndrome or delirium
and cognitive impairment are related with end-of-life and
therefore are not relevant for patients undergoing chemo-
therapy. Other clinical signs, such as dyspnea and weight
loss, have also proven effective to predict life expectancy.
When choosing between chemotherapy and supportive
care alone, patients' preferences should be taken into
account, considering that most patients are willing to
accept chemotherapy for a very small chance of benefit.
Conclusion
The decision to stop chemotherapy is one of the hardest
challenges in oncology practice. Chemotherapy remains
widely prescribed for terminally ill patients despite side
effects and poor efficacy.
From our prospective observational study, we con-
cluded that factors influencing survival on patients with
Advanced Non-Small-Cell lung cancer, who had at least
one line of chemotherapy treatment, were anemia and
poor PS. Larger prospective studies seem necessary to
develop prognostic test scores, adapted to NSCLC, which
may help clinicians estimate patients' survival and make
appropriate recommendations for active or supportive
care to develop prognostic scores, which may help clini-
cians estimate patients' survival and make appropriate
recommendations for active or supportive care.
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